Abstract:Class I HDACs are considered promising targets for cancer due to their role in epigenetic modifications. The main challenges in developing a new, potent and non-toxic class I HDAC inhibitor are selectivity and appropriate pharmacokinetics. The PROTAC technique (Proteolysis Targeting Chimera) is a new method in drug development for the production of active substances that can degrade a protein of interest (POI) instead of inhibiting it. This technique will open the era to produce selective and potent drugs with a high margin of safety. Previously, we reported different inhibitors targeting class I HDACs functionalized with aminobenzamide or hydroxamate groups. In the current research work, we will employ PROTAC technique to develop class I HDAC degraders based on our previously reported inhibitors. We synthesized two series of aminobenzamide-based PROTACs and hydroxamate-based PROTACs and tested them in vitro against class I HDACs. To ensure their degradation, all of them were screened against HDAC2 as representative example of class I. The best candidates were evaluated at different concentrations at various HDAC subtypes. This resulted in the PROTAC (32a) (HI31.1) that degrades HDAC8 with a DC50 of 8.9 nM with a proper margin of selectivity against other isozymes. Moreover, PROTAC 32a is able to degrade HDAC6 with DC50 = 14.3 nM. Apoptotic study on leukemic cells (MV-4-11) displayed more than 50 % apoptosis took place at 100 nM. PROTAC 32a (HI31.1) showed a good margin of safety against normal cell line and proper chemical stability.

Cell-Specific Degradation of Histone Deacetylase Using Warhead-Caged Proteolysis Targeting Chimeras

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Probing class I histone deacetylases (HDAC) with proteolysis targeting chimera (PROTAC) for the development of highly potent and selective degraders

Advances in the Design and Development of PROTAC-mediated HDAC degradation.

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

Enzyme-catalyzed Activation of Pro-PROTAC for Cell-selective Protein Degradation

Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation

Stimuli‐Responsive PROTACs for Controlled Protein Degradation

DNA-templated spatially controlled proteolysis targeting chimeras for CyclinD1-CDK4/6 complex protein degradation

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Development and characterization of the first selective class IIb histone deacetylase degraders

HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

Reversible Assembly of Proteolysis Targeting Chimeras

DNA framework-engineered chimeras platform enables selectively targeted protein degradation

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid